摘要
TAO是一种以眼眶软组织炎性反应、黏多糖沉积及后期组织重塑为特征的自身免疫性疾病，其与甲状腺功能的关系密切。TAO临床表现多变，治疗手段多样，目前国内外缺乏统一的诊断分期和治疗标准，而准确判断病情并制定相应的个体化治疗方案，对TAO患者的预后尤为重要，因此TAO诊治规范化是眼科临床亟待解决的问题。
Thyroid associated ophthalmopathy is a complex autoimmune disease characterized by inflammation of the orbital tissue, hyaluronan deposition and tissue remodeling due to a skewed production of preadipocytic fibroblasts and increased adipogenesis in the late stage. Its progression is strongly related to the functional status of thyroid. So far, there is no consensus on staging, grading and treatment worldwide owning to the complexity of its clinical manifestations and therapies. However, it is of great importance to accurately judge its status and make individualized therapeutic regimen. Therefore, we propose how to standardize the TAO diagnosis and treatment.
作者
钱江
Qian Jiang.(Department of Ophthalmology, Eye ＆ ENT Hospital, Fudan University, Myopia Key Laboratory of Health Ministry, Shanghai 200031, China)
出处
《中华眼科杂志》
CSCD
北大核心
2017年第6期404-407,共4页
Chinese Journal of Ophthalmology
